These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 8647764)
1. Problems encountered in the characterization of IRT beta-lactamase-producing clinical Escherichia coli isolates intermediate-resistant to cephalothin. Chaibi EB; Farzaneh S; Morand A; Peduzzi J; Barthelemy M; Sirot D; Labia R J Antimicrob Chemother; 1996 Jan; 37(1):190-1. PubMed ID: 8647764 [No Abstract] [Full Text] [Related]
2. Novel extended-spectrum TEM-type beta-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalothin. Chanal-Claris C; Sirot D; Bret L; Chatron P; Labia R; Sirot J Antimicrob Agents Chemother; 1997 Mar; 41(3):715-6. PubMed ID: 9056022 [TBL] [Abstract][Full Text] [Related]
3. Patterns of resistance to beta-lactams and characterization of beta-lactamases in Escherichia coli isolates from children in Tunisia. Réjiba S; Kechrid A J Chemother; 2007 Aug; 19(4):382-7. PubMed ID: 17855181 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility to penicillins and cephalosporins in beta-lactamase producing strains of E. coli and relative amount of beta-lactamase produced from these strains. Normark S; Grundström T; Bergström S Scand J Infect Dis Suppl; 1980; suppl 25():23-9. PubMed ID: 7010537 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of loracarbef against TEM extended-spectrum beta-lactamase-producing Escherichia coli strains and its interaction with the enzymes. Prinarakis EE; Tzouvelekis LS; Legakis NJ Chemotherapy; 1998; 44(4):260-4. PubMed ID: 9681202 [TBL] [Abstract][Full Text] [Related]
6. A model system to demonstrate that beta-lactamase-associated antibiotic trapping could be a potential means of resistance. Gutmann L; Williamson R J Infect Dis; 1983 Aug; 148(2):316-21. PubMed ID: 6310004 [TBL] [Abstract][Full Text] [Related]
7. Paradoxical susceptibility to cephalothin and cefamandole of a Klebsiella pneumoniae isolate producing extended-spectrum beta-lactamase (TEM-3). Gaillot O; Mallea M; Philippon A; Pages JM; Simonet M J Antimicrob Chemother; 1996 Jan; 37(1):194-6. PubMed ID: 8647766 [No Abstract] [Full Text] [Related]
8. Lytic activity of a new cephalosporin, cefuroxime, against gram-negative bacteria. Russell AD; Tottle PC Chemotherapy; 1978; 24(6):354-9. PubMed ID: 359269 [TBL] [Abstract][Full Text] [Related]
9. Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group. Chardon H; Farzaneh S; Labia R; Jarlier V; Nicolas MH; Paul G; Poyart C; Sirot D; Sirot J J Antimicrob Chemother; 1995 Jul; 36(1):267-9. PubMed ID: 8537279 [No Abstract] [Full Text] [Related]
10. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase. Cherubin CE; Eng RH; Smith SM; Tan EN J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944 [TBL] [Abstract][Full Text] [Related]
11. Characterization of beta-lactamases responsible for resistance to extended-spectrum cephalosporins in Escherichia coli and Salmonella enterica strains from food-producing animals in the United Kingdom. Liebana E; Gibbs M; Clouting C; Barker L; Clifton-Hadley FA; Pleydell E; Abdalhamid B; Hanson ND; Martin L; Poppe C; Davies RH Microb Drug Resist; 2004; 10(1):1-9. PubMed ID: 15140388 [TBL] [Abstract][Full Text] [Related]
12. [The in vitro effect of a combination of sulbactam with cephalothin and cefazolin on strains of Escherichia coli and Proteus mirabilis which produce beta lactamase]. Múcková M; Milosovic P Bratisl Lek Listy; 1990 Apr; 91(4):303-8. PubMed ID: 2198081 [TBL] [Abstract][Full Text] [Related]
13. High-level cefepime resistance in Escherichia coli from Singapore producing OXA-1 beta-lactamase. Koh TH; Wang G; Koh TY Int J Antimicrob Agents; 2008 Apr; 31(4):382-3. PubMed ID: 18178066 [No Abstract] [Full Text] [Related]
14. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors. Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805 [TBL] [Abstract][Full Text] [Related]
15. Statistical study of intrinsic resistance in Escherichia coli. Roy C; Segura C; Teruel D; Teixell M; Reig R; Hermida M Chemioterapia; 1987 Jun; 6(2 Suppl):197-8. PubMed ID: 3334557 [No Abstract] [Full Text] [Related]
16. Plasmid-determined beta-lactamase indistinguishable from the chromosomal beta-lactamase of Escherichia coli. Bobrowski MM; Matthew M; Barth PT; Datta N; Grinter NJ; Jacob AE; Kontomichalou P; Dale JW; Smith JT J Bacteriol; 1976 Jan; 125(1):149-57. PubMed ID: 1107303 [TBL] [Abstract][Full Text] [Related]
17. Relationships between in vitro susceptibility and efficacy in experimental mouse infection-protection assay of cefazolin and cephalothin using Escherichia coli strains. Uri JV; Actor P; Phillips L; Guarini JR; Weisbach JA Chemotherapy; 1976; 22(5):313-8. PubMed ID: 780071 [TBL] [Abstract][Full Text] [Related]
18. [Routine detection of beta-lactamases TEM resistant to inhibitors (IRT) and oxacillinases (OXA) in Escherichia coli]. Libert JM; Naudin F; Mougeot C; Sirot D Pathol Biol (Paris); 1997 Jan; 45(1):34-40. PubMed ID: 9097844 [TBL] [Abstract][Full Text] [Related]
19. [Research regarding extended-spectrum beta-lactamases produced by enterobacteria strains]. Copăcianu B; Tuchiluş C; Poiata A; Iancu LS Rev Med Chir Soc Med Nat Iasi; 2010; 114(3):896-9. PubMed ID: 21243821 [TBL] [Abstract][Full Text] [Related]